199 related articles for article (PubMed ID: 32214351)
1. PCC0208025 (BMS202), a small molecule inhibitor of PD-L1, produces an antitumor effect in B16-F10 melanoma-bearing mice.
Hu Z; Yu P; Du G; Wang W; Zhu H; Li N; Zhao H; Dong Z; Ye L; Tian J
PLoS One; 2020; 15(3):e0228339. PubMed ID: 32214351
[TBL] [Abstract][Full Text] [Related]
2. Combined SEP and anti-PD-L1 antibody produces a synergistic antitumor effect in B16-F10 melanoma-bearing mice.
Hu Z; Ye L; Xing Y; Hu J; Xi T
Sci Rep; 2018 Jan; 8(1):217. PubMed ID: 29317734
[TBL] [Abstract][Full Text] [Related]
3. An Immunomodulatory Gallotanin-Rich Fraction From
Lasso P; Gomez-Cadena A; Urueña C; Donda A; Martinez-Usatorre A; Romero P; Barreto A; Fiorentino S
Front Immunol; 2020; 11():584959. PubMed ID: 33312174
[TBL] [Abstract][Full Text] [Related]
4. Correction: PCC0208025 (BMS202), a small molecule inhibitor of PD-L1, produces an antitumor effect in B16-F10 melanoma-bearing mice.
PLOS ONE Staff
PLoS One; 2021; 16(4):e0251020. PubMed ID: 33909703
[TBL] [Abstract][Full Text] [Related]
5. A chemical conjugation of JQ-1 and a TLR7 agonist induces tumoricidal effects in a murine model of melanoma via enhanced immunomodulation.
Wang X; Yu B; Cao B; Zhou J; Deng Y; Wang Z; Jin G
Int J Cancer; 2021 Jan; 148(2):437-447. PubMed ID: 32683685
[TBL] [Abstract][Full Text] [Related]
6. Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model.
Meng X; Du G; Ye L; Sun S; Liu Q; Wang H; Wang W; Wu Z; Tian J
Int J Immunopathol Pharmacol; 2017 Sep; 30(3):215-226. PubMed ID: 28604143
[TBL] [Abstract][Full Text] [Related]
7. Rational Design of a Robust Antibody-like Small-Molecule Inhibitor Nanoplatform for Enhanced Photoimmunotherapy.
Shang Q; Zhou S; Jiang Y; Wang D; Wang J; Song A; Luan Y
ACS Appl Mater Interfaces; 2020 Sep; 12(36):40085-40093. PubMed ID: 32791825
[TBL] [Abstract][Full Text] [Related]
8. Novel Biphenyl Pyridines as Potent Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.
Wang T; Cai S; Wang M; Zhang W; Zhang K; Chen D; Li Z; Jiang S
J Med Chem; 2021 Jun; 64(11):7390-7403. PubMed ID: 34056906
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 4-phenyl-1H-indazole derivatives as novel small-molecule inhibitors targeting the PD-1/PD-L1 interaction.
Xu C; Sun Z; Zhang X; Zang Q; Yang Z; Li L; Yang X; He Y; Ma Z; Chen J
Bioorg Chem; 2024 Jun; 147():107376. PubMed ID: 38640722
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction as Potential Anticancer Agents.
Cheng B; Ren Y; Niu X; Wang W; Wang S; Tu Y; Liu S; Wang J; Yang D; Liao G; Chen J
J Med Chem; 2020 Aug; 63(15):8338-8358. PubMed ID: 32667799
[TBL] [Abstract][Full Text] [Related]
11. PCC0208018 exerts antitumor effects by activating effector T cells.
Ge M; Hu Z; Chen X; Du G; Wang H; Liu R; Ye L; Tian J
Int J Immunopathol Pharmacol; 2019; 33():2058738419843366. PubMed ID: 30968715
[TBL] [Abstract][Full Text] [Related]
12. B16 melanoma control by anti-PD-L1 requires CD8+ T cells and NK cells: application of anti-PD-L1 Abs and Trp2 peptide vaccines.
Ji S; Lee J; Lee ES; Kim DH; Sin JI
Hum Vaccin Immunother; 2021 Jul; 17(7):1910-1922. PubMed ID: 33522416
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy.
Zhang H; Xia Y; Yu C; Du H; Liu J; Li H; Huang S; Zhu Q; Xu Y; Zou Y
Molecules; 2021 Jun; 26(11):. PubMed ID: 34199417
[TBL] [Abstract][Full Text] [Related]
14. A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti-PD-(L)1 and Anti-CTLA-4 in Preclinical Models.
Willingham SB; Ho PY; Hotson A; Hill C; Piccione EC; Hsieh J; Liu L; Buggy JJ; McCaffery I; Miller RA
Cancer Immunol Res; 2018 Oct; 6(10):1136-1149. PubMed ID: 30131376
[TBL] [Abstract][Full Text] [Related]
15. Combination of Chidamide-Mediated Epigenetic Modulation with Immunotherapy: Boosting Tumor Immunogenicity and Response to PD-1/PD-L1 Blockade.
Tu K; Yu Y; Wang Y; Yang T; Hu Q; Qin X; Tu J; Yang C; Kong L; Zhang Z
ACS Appl Mater Interfaces; 2021 Aug; 13(33):39003-39017. PubMed ID: 34433253
[TBL] [Abstract][Full Text] [Related]
16. T cell mediated immunity after combination therapy with intralesional PV-10 and blockade of the PD-1/PD-L1 pathway in a murine melanoma model.
Liu H; Weber A; Morse J; Kodumudi K; Scott E; Mullinax J; Sarnaik AA; Pilon-Thomas S
PLoS One; 2018; 13(4):e0196033. PubMed ID: 29694419
[TBL] [Abstract][Full Text] [Related]
17. Melanoma Cancer Immunotherapy Using PD-L1 siRNA and Imatinib Promotes Cancer-Immunity Cycle.
Li C; Han X
Pharm Res; 2020 May; 37(6):109. PubMed ID: 32476052
[TBL] [Abstract][Full Text] [Related]
18. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
[TBL] [Abstract][Full Text] [Related]
19. Novel Treatment of Melanoma: Combined Parasite-Derived Peptide GK-1 and Anti-Programmed Death Ligand 1 Therapy.
Vera-Aguilera J; Perez-Torres A; Beltran D; Villanueva-Ramos C; Wachtel M; Moreno-Aguilera E; Vera-Aguilera C; Ventolini G; Martínez-Zaguilán R; Sennoune SR
Cancer Biother Radiopharm; 2017 Mar; 32(2):49-56. PubMed ID: 28301259
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy.
Wang F; Ye W; Wang S; He Y; Zhong H; Wang Y; Zhu Y; Han J; Bing Z; Ji S; Liu H; Yao X
Neoplasia; 2021 Mar; 23(3):281-293. PubMed ID: 33529880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]